Health Wire Taiwan: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Taiwan.

Press releases published on July 10, 2026

14 hours ago

AAIC 2026 逾 140 份学术报告均采用 Alamar Biosciences NULISA 数据，彰显阿尔茨海默病血液生物标志物分析领域的进展

Indeterminate GlobeNewswire

14 hours ago

Alamar Biosciences 的 NULISA 數據將於 AAIC 2026 上超過 140 場科學簡報會中亮相，突顯基於血液的阿茲海默症生物標記剖析之最新進展

Indeterminate GlobeNewswire

15 hours ago

Canadian Red Cross opens appeal to support people impacted by flooding in Manitoba

Indeterminate GlobeNewswire

15 hours ago

La Croix-Rouge canadienne met sur pied un fonds de secours pour aider les personnes touchées par les inondations au Manitoba

Indeterminate GlobeNewswire

16 hours ago

GuideAI Health Announces Marketing and Communications Programs

Indeterminate GlobeNewswire

16 hours ago

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

16 hours ago

SoliVana Wellness Lab Celebrates 3 years in Redwood City as the Bay Area's First Dedicated Nervous System Recovery Center

Indeterminate GlobeNewswire

17 hours ago

VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister

Indeterminate GlobeNewswire

17 hours ago

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

17 hours ago

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

17 hours ago

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

17 hours ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Jul. 10, 2026

Elevar Therapeutics Receives FDA Complete Response Letter for Combination of Rivoceranib and Camrelizumab as a First-line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Indeterminate GlobeNewswire

Jul. 10, 2026

AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

Indeterminate GlobeNewswire

Jul. 10, 2026

AB Science fait le point sur son programme clinique avec l’arrêt de certaines études cliniques non prioritaires en vue de se concentrer sur deux programmes cliniques

Indeterminate GlobeNewswire

Jul. 10, 2026

Cosmos Health Launches Subscription Model

Indeterminate GlobeNewswire

Jul. 10, 2026

FDA Proposes Rule to Modernize Drug Manufacturing Registration

Indeterminate GlobeNewswire

Jul. 10, 2026

Microscopy Market to Grow from USD 8.81 Billion in 2025 to USD 11.44 Billion by 2031, at a CAGR of 5.5% – MarketsandMarkets™

Indeterminate GlobeNewswire

Jul. 10, 2026

AI Revolutionizes Cardiovascular Drug Development with $1.4+ Billion in Strategic Investments

Indeterminate GlobeNewswire

Jul. 10, 2026

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum

Indeterminate GlobeNewswire